• Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Fisher, R.I., Hagenbeek, A., Zucca, E., Rosen, S.T., Stroobants, S., Lister, A., Hoppe, R.T., Dreyling, M., Tobinai, K., Vose, J.M., Connors, J.M., Federico, M. & Diehl, V. (2007) Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25, 579586.
  • Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P. & Gisselbrecht, C. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine, 346, 235242.
  • Dunleavy, K., Healey Bird, B.R., Pittaluga, S., Grant, N., Shovlin, M., Little, R., Yarchoan, R., Steinberg, S., Jaffe, E.S., Janik, J. & Wilson, W.H. (2007) Efficacy and toxicity of dose-adjusted EPOCH-rituximab in adults with newly diagnosed Burkitt lymphoma. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings Part I), 25, 8035.
  • Jaffe, E.S., Harris, N.L., Stein, H. & Vardiman, J.W. (2001) World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon, France.
  • Johnson, N.A., Boyle, M., Bashashati, A., Leach, S., Brooks-Wilson, A., Sehn, L.H., Chhanabhai, M., Brinkman, R.R., Connors, J.M., Weng, A.P. & Gascoyne, R.D. (2009) Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival. Blood, 113, 37733780.
  • Karantanis, D., Durski, J.M., Lowe, V.J., Nathan, M.A., Mullan, B.P., Georgiou, E., Johnston, P.B. & Wiseman, G.A. (2009) 18F-FDG PET and PET–CT in Burkitt’s lymphoma. European Journal of Radiology, 75, e68e73.
  • Kasamon, Y.L. & Wahl, R.L. (2008) FDG PET and risk-adapted therapy in Hodgkin’s and non-Hodgkin’s lymphoma. Current Opinion in Oncology, 20, 206219.
  • Magrath, I., Adde, M., Shad, A., Venzon, D., Seibel, N., Gootenberg, J., Neely, J., Arndt, C., Nieder, M., Jaffe, E., Wittes, R.A. & Horak, I.D. (1996) Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. Journal of Clinical Oncology, 14, 925934.
  • Hummel, M., Bentink, S., Berger, H., Klapper, W., Wessendorf, S., Barth, T.F.E., Bernd, H-W., Cogliatti, S.B., Dierlamm, J., Feller, A.C., Hansmann, M-L., Haralambieva, E., Harder, L., Hasenclever, D., Kühn, M., Lenze, D., Lichter, P., Martin-Subero, J.I., Möller, P., Müller-Hermelink, H-K., Ott, G., Parwaresch, R.M., Pott, C., Rosenwald, A., Rosolowski, M., Schwaenen, C., Stürzenhofecker, B., Szczepanowski, M., Trautmann, H., Wacker, H-H., Spang, R., Loeffler, M., Trümper, L., Stein, H., & Siebert, R. for the Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe. (2006) A biologic definition of Burkitt’s lymphoma from transcriptional and genomic profiling. New England Journal of Medicine, 354, 24192430.
  • Mead, G.M., Sydes, M.R., Walewski, J., Grigg, A., Hatton, C.S., Pescosta, N., Guarnaccia, C., Lewis, M.S., McKendrick, J., Stenning, S.P. & Wright, D. (2002) An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt’s lymphoma: results of United Kingdom Lymphoma Group LY06 study. Annals of Oncology, 13, 12641274.
  • Mead, G.M., Barrans, S.L., Qian, W., Walewski, J., Radford, J.A., Wolf, M., Clawson, S.M., Stenning, S.P., Yule, C.L. & Jack, A.S. (2008) A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood, 112, 22482260.
  • Pfreundschuh, M., Trümper, L., Osterborg, A., Pettengell, R., Trneny, M., Imrie, K., Ma, D., Gill, D., Walewski, J., Zinzani, P.L., Stahel, R., Kvaloy, S., Shpilberg, O., Jaeger, U., Hansen, M., Lehtinen, T., López-Guillermo, A., Corrado, C., Scheliga, A., Milpied, N., Mendila, M., Rashford, M., Kuhnt, E. & Loeffler, M. (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncology, 7, 379391.
  • Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A. & Stein, H. (2008) WHO Classification of Tumours of Haematological and Lymphoid Tissues. WHO Press, Lyon France.
  • Thomas, D.A., Faderl, S., O’Brien, S., Bueso-Ramos, C., Cortes, J., Garcia-Manero, G., Giles, F.J., Verstovsek, S., Wierda, W.G., Pierce, S.A., Shan, J., Brandt, M., Hagemeister, F.B., Keating, M.J., Cabanillas, F. & Kantarjian, H. (2006) Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer, 106, 15691580.
  • WHO (1979) WHO Handbook for Reporting Results of Cancer Treatment. World Health Organization, Geneva.
  • Yokohama, A., Tsukamoto, N., Uchiumi, H., Handa, H., Matsushima, T., Karasawa, M., Murakami, H. & Nojima, Y. (2004) Durable remission induced by rituximab-containing chemotherapy in a patient with primary refractory Burkitt’s lymphoma. Annals of Haematology, 83, 120123.